Product Information
CEFTRIAXONE 2 GM VIAL is a generic product labeled by Hospira Inc., priced at $2.8330 per EA under NDC 00409733520. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on May 9, 2005. Its Orange Book therapeutic-equivalence code is AP.
Strength
2 g/1
Manufacturer
Hospira Inc.NDC
00409733520
Classification
Generic
Dosage Form
INJECTION, POWDER, FOR SOLUTION
Route
INTRAMUSCULAR; INTRAVENOUS
Effective Date
9/23/2026
Active Ingredients
CEFTRIAXONE SODIUMApproval Type
Generic (ANDA)
FDA Application
ANDA065169FDA Approved
5/9/2005
TE Code
AP
On Market Since
5/9/2005
Pharmacological Classes
Price Statistics
The NADAC for CEFTRIAXONE 2 GM VIAL has been published 129 times since Apr 17, 2024, and over the history we have for it it has declined 4.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.8330 per EA |
|---|---|
| All-time high | $3.0835 (Sep 11, 2024) |
| All-time low | $2.2684 (Oct 22, 2025) |
| 52-week high | $2.8330 |
| 52-week low | $2.2684 |
| Median price | $2.5922 |
| Average price | $2.6294 |
| Largest weekly change | -11.8% (May 22, 2024) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Hospira Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ceftriaxone Sodium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cephalosporin Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CEFTRIAXONE 2 GM VIAL?
The current National Average Drug Acquisition Cost (NADAC) for CEFTRIAXONE 2 GM VIAL, manufactured by Hospira Inc., is $2.8330 per EA (NDC 00409733520), effective Sep 30, 2026.
How has the price of CEFTRIAXONE 2 GM VIAL changed over time?
Over the history we have for it, the NADAC for CEFTRIAXONE 2 GM VIAL has declined 4.9%. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for CEFTRIAXONE 2 GM VIAL?
Since Apr 17, 2024, the NADAC for CEFTRIAXONE 2 GM VIAL has ranged from a low of $2.2684 (Oct 22, 2025) to a high of $3.0835 (Sep 11, 2024), with a median of $2.5922 per EA.
Are there cheaper alternatives to CEFTRIAXONE 2 GM VIAL?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CEFTRIAXONE 2 GM VIAL in a comparable dosage form, but none are currently priced below it.
Who manufactures CEFTRIAXONE 2 GM VIAL?
CEFTRIAXONE 2 GM VIAL (NDC 00409733520) is labeled by Hospira Inc., and CMS classifies it as a generic product.